A novel ciprofloxacin-resistant subclade of h58. Salmonella typhi is associated with fluoroquinolone treatment failure

Duy Pham Thanh, Abhilasha Karkey, Sabina Dongol, Nhan Ho Thi, Corinne N Thompson, Maia A Rabaa, Amit Arjyal, Kathryn E Holt, Vanessa Wong, Nga Tran Vu Thieu, Phat Voong Vinh, Tuyen Ha Thanh, Ashish Pradhan, Saroj Kumar Shrestha, Damoder Gajurel, Derek Pickard, Christopher M. Parry, Gordon Dougan, Marcel Wolbers, Christiane DolecekGuy E. Thwaites, Buddha Basnyat, Stephen Baker

Research output: Contribution to journalArticleResearchpeer-review

48 Citations (Scopus)

Abstract

The interplay between bacterial antimicrobial susceptibility, phylogenetics and patient outcome is poorly understood. During a typhoid clinical treatment trial in Nepal, we observed several treatment failures and isolated highly fluoroquinolone-resistant Salmonella Typhi (S. Typhi). Seventy-eight S. Typhi isolates were genome sequenced and clinical observations, treatment failures and fever clearance times (FCTs) were stratified by lineage. Most fluoroquinolone-resistant S. Typhi belonged to a specific H58 subclade. Treatment failure with S. Typhi-H58 was significantly less frequent with ceftriaxone (3/31; 9.7%) than gatifloxacin (15/34; 44.1%)(Hazard Ratio 0.19, p=0.002). Further, for gatifloxacin-treated patients, those infected with fluoroquinolone-resistant organisms had significantly higher median FCTs (8.2 days) than those infected with susceptible (2.96) or intermediately resistant organisms (4.01)(p<0.001). H58 is the dominant S. Typhi clade internationally, but there are no data regarding disease outcome with this organism. We report an emergent new subclade of S. Typhi-H58 that is associated with fluoroquinolone treatment failure.

Original languageEnglish
Article numbere14003
Number of pages13
JournaleLife
Volume5
DOIs
Publication statusPublished - 14 Mar 2016
Externally publishedYes

Cite this